Premium
The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses
Author(s) -
Kim Soo Young,
Choi Yoon Young,
An Ji Yeong,
Shin Hyun Beak,
Jo Ara,
Choi Hyeji,
Seo Sang Hyuk,
Bang HuiJae,
Cheong JaeHo,
Hyung Woo Jin,
Noh Sung Hoon
Publication year - 2015
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.29449
Subject(s) - microsatellite instability , medicine , chemotherapy , cancer , hazard ratio , stage (stratigraphy) , oncology , gastroenterology , confidence interval , population , gastrectomy , biology , allele , microsatellite , paleontology , biochemistry , environmental health , gene
We previously reported that the prognosis of microsatellite instability high (MSI‐H) gastric cancer is similar to that of MSI‐low/microsatellite stable (MSI‐L/MSS) gastric cancer. The reason for this seemed to be related to the effects of chemotherapy. To verify this hypothesis, we expanded the study population and reanalyzed the prognosis of MSI‐H gastric cancer. Data from 1,276 patients with Stage II and III gastric cancer who underwent gastrectomy with curative intent between January 2005 and June 2010 were reviewed. The prognosis of MSI‐H tumors in comparison with MSI‐L/MSS tumors was analyzed, according to the administration of chemotherapy and other clinicopathologic features. A total of 361 (28.3%) patients did not receive chemotherapy (MSI‐H = 47 and MSI‐L/MSS = 314), whereas 915 (71.7%) patients did receive chemotherapy (MSI‐H = 58 and MSI‐L/MSS = 857). The hazard ratio of MSI‐H versus MSI‐L/MSS was 0.49 (95% confidence interval: 0.26–0.94, p = 0.031) when chemotherapy was not received and 1.16 (95% confidence interval: 0.78–1.71, p = 0.466) when chemotherapy was received. In subgroup analyses, the prognosis of MSI‐H was better in Stage III, women, with lymph node metastasis, and undifferentiated histology subgroups when chemotherapy was not received. However, in patients treated with chemotherapy, prognosis was worse for MSI‐H tumors in Stage III, undifferentiated histology, and diffuse type subgroups of gastric cancer. In conclusion, MSI‐H tumors were associated with a good prognosis in Stage II and III gastric cancer when patients were treated by surgery alone, and the benefits of MSI‐H status were attenuated by chemotherapy.